Drug Profile
Research programme: bone cell regulators - Bone Medical
Alternative Names: BN 005; BN 008Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bone Medical
- Developer Bone Medical; University of Queenslands Institute for Molecular Bioscience
- Class Peptides
- Mechanism of Action Osteoblast stimulants; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Osteoporosis in Australia
- 28 Jan 2013 Early research is ongoing in Australia
- 13 Aug 2007 Early research in Osteoporosis in Australia (unspecified route)